Kadmon Holdings Inc.

07/19/2021 | Press release | Distributed by Public on 07/19/2021 14:06

REZUROCK is approved for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy (Form 8-K)